Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc.（INTS）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · INTS · 截至 2025年9月30日
股东结构概览
26
机构持有人数
▼ 1 vs Q2
$721,188
机构持仓总市值
▲ $114,576 vs Q2
1.89M
总流通股
freeFloat 53.88%
2.96M
13F 申报持股数
▲ 982,735 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
INTS 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
SAPIENT CAPITAL LLC biological products, (no diagnostic substances) | 976.8K | 28.81% | 28.81% | $239.71M | Oct 17, 2025 | — held |
SENTINUS, LLC biological products, (no diagnostic substances) | 481.2K | 14.19% | 14.19% | $116.78M | Nov 14, 2025 | ▲ 281.9K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 258.9K | 7.63% | 7.63% | $62.83M | Nov 12, 2025 | ▲ 186.1K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 255.9K | 7.55% | 7.55% | $62.19M | Nov 7, 2025 | ▲ 215.3K |
MESIROW FINANCIAL INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 200.0K | 5.90% | 5.90% | $48.54M | Nov 12, 2025 | ▲ 90.0K |
UBS GROUP AG biological products, (no diagnostic substances) | 136.2K | 4.02% | 4.02% | $33.10M | Nov 13, 2025 | ▲ 127.0K |
BROWN ADVISORY INC biological products, (no diagnostic substances) | 130.1K | 3.84% | 3.84% | $31.57M | Nov 14, 2025 | — held |
SIGMA PLANNING CORP biological products, (no diagnostic substances) | 69.2K | 2.04% | 2.04% | $16.79M | Nov 10, 2025 | — held |
WARBERG ASSET MANAGEMENT LLC biological products, (no diagnostic substances) | 60.0K | 1.77% | 1.77% | $14.56M | Nov 6, 2025 | ▼ 8.4K |
STONEBRIDGE FINANCIAL GROUP, LLC biological products, (no diagnostic substances) | 54.4K | 1.60% | 1.60% | $13.20M | Oct 20, 2025 | ▲ 37.9K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
10
增持
+957.0K 股5
新建仓
首次建仓1
减持
−8.4K 股6
清仓
完全退出净股数变化（前50家）
+948.6K
+957.0K / −8.4K
净新增持仓人
+8
新建 5 个 / 退出 6 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
INTS 内幕交易记录
数据来源：SEC Form 4
9
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
BENDER LEWIS H President and CEO | Mar 26, 2026 | Award | 37,749 | $6.11 | $230.6K | 118.5K | Form 4 ↗ |
Wesolowski John M Principal Accounting Officer | Dec 31, 2025 | Award | 8,918 | $0.26 | $2.3K | 85.4K | Form 4 ↗ |
Talamo Joseph Chief Financial Officer | Dec 31, 2025 | Award | 14,482 | $0.26 | $3.8K | 28.7K | Form 4 ↗ |
Wesolowski John M Principal Accounting Officer | Jun 30, 2025 | Award | 69,745 | $0.26 | $18.2K | 76.4K | Form 4 ↗ |
Talamo Joseph Chief Financial Officer | Jun 30, 2025 | Award | 14,179 | $0.26 | $3.7K | 14.2K | Form 4 ↗ |
DUBIN THOMAS I H director | May 2, 2025 | Award | 50,000 | $0.57 | $28.5K | 50.0K | Form 4 ↗ |
Donovan Daniel director | May 2, 2025 | Award | 50,000 | $0.57 | $28.5K | 50.0K | Form 4 ↗ |
GOLDBERG MARK A director | May 2, 2025 | Award | 50,000 | $0.57 | $28.5K | 50.0K | Form 4 ↗ |
Leahy Emer director | May 2, 2025 | Award | 50,000 | $0.57 | $28.5K | 50.0K | Form 4 ↗ |
Wesolowski John M Principal Accounting Officer | May 2, 2025 | Award | 100,000 | $0.57 | $57.0K | 100.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Intensity Therapeutics, Inc.（INTS）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 46.12%，散户及公众持股约占剩余的 0.00%。
Intensity Therapeutics, Inc. 最大机构股东为 SAPIENT CAPITAL LLC，截至 September 30, 2025 持有约 976,797 股，占总流通股的 28.81%。
目前共有 26 家机构持有 INTS 股票，合计持仓市值约 $721,188，数据来源为最新 SEC 13F 申报。
常见问题
INTS ownershipIntensity Therapeutics, Inc.（INTS）主要由机构投资者持有，机构持股约 100.0%。最大股东为 SAPIENT CAPITAL LLC，持股比例 28.81%。内部人员持股约 46.12%。数据来源 SEC Form 13F，截至 September 30, 2025。